OPKO Health, Inc.

NASDAQ:OPK

Biotechnology

Healthcare
$1.69 +0.52%

+$0.01 today

Market cap
$1.25B
Beta
1.49
P/E (TTM)
-5.1
EPS (TTM)
-$0.28
52W Low $0.98High $1.60

Volume 3.06M

Average 2.59M

OPK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OPKO Health, Inc.NASDAQ: OPK

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $29.2M fell 5.3% year over year, behind the +7.2% change in trailing-twelve-month research & development. Sequentially, it fell 10.9% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Research & development amounted to 20.4% of revenue in FY2025, up 5.7 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.3% toward the trailing-twelve-month pace of +7.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29.2M-10.9% QoQ
Last fiscal yearDec 2025
$124.03M+17.9% YoY
LTMMar 2026
$122.39M+7.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.3%——
1 year+17.9%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
124.03M USD
Year-over-year change
+17.9%
4-year CAGR
+12.7%

Research & Development vs competitors

How OPK compares with its peers on the latest reported figures

  • OPK's LTM Mar 2026 research & development of $122.39M is the 3rd highest of the 11 companies compared; the peer median is $54.69M.
  • Its year-over-year change of +7.2% is the 7th highest of 11, against a peer median of +8.5%.
  • Research & development amounts to 21.1% of revenue for OPK, versus a peer median of 15.3%.
OPK Competitors Peer median
Research & Development for OPK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
OPKOPKO Health, Inc.LTM Mar 2026$122.39M +7.2%+18.8%21.1%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
MDXHMDxHealth S.A.FY2025$10.35M -1.9%+11.1%9.6%
XGNExagen Inc.LTM Mar 2026$6.52M +16.5%-14.1%9.5%
Peer median (excluding OPK) $54.69M+8.5%+6.9%15.3%

Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1B863.5M713.14M606.88M
Cost of Revenue1.19B715.98M545.37M402.11M478.83M
Gross Profit581.52M288.22M318.13M311.03M128.05M
Gross Margin32.8%28.7%36.8%43.6%21.1%
Research & Development76.85M73.89M89.59M105.21M124.03M
Selling, General & Admin468.86M372.67M300.56M304.22M223M
Operating Expenses562.77M514.47M475.15M463.1M347.04M
Depreciation & Amortization78.72M108.66M105.3M98.18M91.63M
EBITDA83.57M(270.81M)(65.52M)135.28M(41.3M)
EBITDA Margin4.7%-27.0%-7.6%19.0%-6.8%
Operating Income18.75M(226.25M)(157.02M)(152.07M)(218.99M)
Operating Margin1.1%-22.5%-18.2%-21.3%-36.1%
Interest Income28K1.98M3.98M8.43M14.81M
Interest Expense18.88M12.06M13.51M47.47M108.46M
Other Income / Expenses(33.4M)(165.65M)(27.41M)141.7M(22.41M)
Income Before Tax(14.65M)(391.9M)(184.43M)(10.36M)(241.39M)
Pre-Tax Margin-0.8%-39.0%-21.4%-1.5%-39.8%
Income Tax Expense15.49M(63.5M)4.44M42.84M(15.71M)
Net Income(30.14M)(328.41M)(188.86M)(53.22M)(225.68M)
Net Margin-1.7%-32.7%-21.9%-7.5%-37.2%
EPS (Basic)(0.05)(0.46)(0.25)(0.08)(0.30)
EPS (Diluted)(0.05)(0.46)(0.25)(0.08)(0.30)
Weighted Avg Shares648.08M719.06M751.77M694.02M751.13M
Weighted Avg Shares (Diluted)648.08M719.06M751.77M694.02M751.13M

OPKO Health, Inc.

NASDAQ:OPK

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.